Members of the Erwiniaceae family, which can be found saprophytic in humans, have been identified several times as an infectious agent after their first identification in 1920. Erwinia persicina was first identified as a plant pathogen by being isolated from cucumber, tomato and banana in 1990, and it was shown to cause disease in many plant species in the following years. E.persicina was diagnosed as a urinary tract infection agent in an 88-year-old female patient in 1998. Our case, a 30-year-old male patient, was hospitalized for perihilar cholangiocarcinoma while being examined with the complaint of abdominal pain. In preparation for the operation, external drainage from the left lobe biliary tract was performed. The same bacterial growth was detected in the three bile fluid cultures of the patient taken on different dates. The bacterium was identified as E.persicina by MALDI-TOF Microflex LT/SH Smart MS (Bruker Daltonics, Germany) and Erwinia rhapontici with VITEK MS (Biomerieux, France), Rahnella aquatilis with VITEK 2 automated system, Pantoea agglomerans with BD Phoenix™ M50 (BD Diagnostics, USA) automated system. E.persicina identification was also obtained by Sanger sequencing. Antibiotic susceptibility results were evaluated according to the non-species related breakpoints criteria of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). While resistance was found to cefuroxime and cefazolin, the isolate was found to be sensitive to many other beta-lactam antibiotics, quinolones and aminoglycosides. E.persicina is a bacterium that is rarely isolated as an infectious agent in humans. The reason for this may be that it is a plant pathogen on the one hand, and mistakes made in its diagnosis on the other. Many identification systems do not have this bacterium in their library. In this case report, our aim was to emphasize that mistakes made in the diagnosis of E.persicina may play a role in the rare occurence of the agent.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5578/mb.20229716 | DOI Listing |
Sci Rep
January 2025
Department of Radiology and Nuclear Medicine, University Hospital Brno, Brno, 625 00, Czechia.
Biliary drainage is then one of the necessary procedures to help patients suffering from icterus to reduce serum bilirubin levels and relieve symptoms. The aim of this study was identifying risk factors for survival in patients with cholangiocarcinoma (CCA) treated with percutaneous transhepatic biliary drainage (PTBD) and to develop a simple scoring system predicting survival from PTBD insertion. This single-centre retrospective study included 175 consecutive patients undergoing PTBD for extrahepatic CCA (perihilar and distal).
View Article and Find Full Text PDFArq Bras Cir Dig
January 2025
Pontificia Universidad Católica de Chile, Department of Digestive Surgery - Santiago, Chile.
Background: Perihilar cholangiocarcinoma presents unique challenges in perioperative management, requiring a comprehensive approach to optimize patient outcomes.
Aims: This case study focuses on the multidisciplinary management and innovative interventions performed in the perioperative care of a patient with hilar cholangiocarcinoma.
Methods: A comprehensive assessment and treatment strategy involving neoadjuvant therapy and interventional radiology techniques were implemented.
Cureus
December 2024
Interventional Cardiology, Lee Health, Fort Myers, USA.
Managing acute coronary syndrome (ACS) in patients with a recent history of gastrointestinal bleeding presents a unique and challenging clinical dilemma, necessitating a careful balance between minimizing ischemic risk and avoiding potentially life-threatening rebleeding. Standard treatment for ACS typically involves dual antiplatelet therapy (DAPT) to prevent recurrent thrombotic events. However, in patients with recent gastrointestinal hemorrhage or significant anemia, these therapies may substantially increase the risk of life-threatening bleeding, complicating the decision-making process and often leading to conservative management strategies.
View Article and Find Full Text PDFEuroasian J Hepatogastroenterol
December 2024
Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India.
Background: The purpose of the present study was to evaluate clinicopathological characteristics, patterns of recurrence, survival outcomes, and implications for the addition of chemoradiotherapy for patients with resected perihilar and intrahepatic cholangiocarcinoma (CCA).
Materials And Methods: For the present retrospective study, we identified 38 and 10 patients with resected perihilar and intrahepatic CCA. In perihilar CCA, adjuvant treatment was given as chemotherapy ( = 13) or chemoradiotherapy ( = 10).
Cancers (Basel)
January 2025
Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, University of Salamanca, IBSAL, CIBERehd, Campus M. Unamuno s/n, 37007 Salamanca, Spain.
Cholangiocarcinoma (CCA) is a group of complex and heterogeneous tumors originating from the epithelial cells of bile ducts that can occur in intrahepatic, perihilar, or distal localizations [...
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!